Clinical Trials
38 trialsNCT01932697 2026-02-10
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Mayo Clinic
Phase 2 Completed
NCT03487549 2024-11-27
COVE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT03981822 2024-11-27
CARE-1
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT02258659 2024-09-24
OPTIMA
University of Chicago
Phase 2 Completed
NCT06439433 2024-06-03
ALA-PDT in Patients With CIN2 in p16-positivity and High-risk HPV Infection
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT01084083 2023-06-28
Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT01693783 2022-11-08
Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04436133 2022-05-06
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
National Vaccine and Serum Institute, China
Phase 2 Completed
NCT02482428 2021-01-05
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
Novartis
Phase 2 Completed
NCT01209325 2020-08-11
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males
AIDS Malignancy Consortium
Phase 2 Completed
NCT00586339 2020-01-03
Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females
GlaxoSmithKline
Phase 2 Completed
NCT00359619 2020-01-02
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT00231413 2019-12-12
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
GlaxoSmithKline
Phase 2 Completed
NCT02631863 2019-07-08
Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT03584308 2019-05-22
Efficacy of VIUSIDĀ® Plus GLIZIGENĀ® in Patients With Papilloma Virus Esophageal
Catalysis SL
Phase 2 Completed
NCT00309166 2018-09-17
Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.
GlaxoSmithKline
Phase 2 Completed
NCT00316693 2018-09-04
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
GlaxoSmithKline
Phase 2 Completed
NCT02048020 2018-08-14
Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02724254 2018-07-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
Vaxart
Phase 2 Completed
NCT00546078 2018-06-26
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
GlaxoSmithKline
Phase 2 Completed
NCT01585428 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03372395 2017-12-13
Probiotic Implementation as Help in Solving Vaginal Infections
University of Roma La Sapienza
Phase 2 Completed
NCT02139267 2017-07-12
Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia
Genexine, Inc.
Phase 2 Completed
NCT02015260 2017-05-03
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
University of Aberdeen
Phase 2 Completed
NCT00411749 2017-04-21
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00378560 2017-04-17
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00518336 2016-12-09
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
GlaxoSmithKline
Phase 2 Completed
NCT00120848 2016-11-04
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
GlaxoSmithKline
Phase 2 Completed
NCT00693615 2016-09-16
Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females
GlaxoSmithKline
Phase 2 Completed
NCT00693966 2016-09-16
Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females
GlaxoSmithKline
Phase 2 Completed
NCT00689741 2016-09-12
Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women
GlaxoSmithKline
Phase 2 Completed
NCT00520598 2015-11-26
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00703196 2015-10-08
Folic Acid Clinical Trial for the Prevention of Cervical Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT00365716 2015-10-07
Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00551187 2015-06-08
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00303823 2015-05-05
Green Tea Extract in Preventing Cervical Cancer in Patients With Human Papillomavirus and Low-Grade Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00054041 2013-01-24
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
National Cancer Institute (NCI)
Phase 2 Completed